Withaferin A disrupts ubiquitin-based NEMO reorganization induced by canonical NF-κB signaling

Experimental Cell Research

Volumn 331, Issue 1, 2015, Pages 58-72

  Jackson, Shawn S ^a,b   Oberley, Christopher ^a   Hooper, Christopher P ^a,b   Grindle, Kreg ^c   Wuerzberger Davis, Shelly ^a   Wolff, Jared ^c   McCool, Kevin ^a,b   Rui, Lixin ^c   Miyamoto, Shigeki ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

ABC type diffuse large B cell lymphoma; Apoptosis; IKK; NEMO; NEMO foci; NF B; Ubiquitin; Withaferin A

Indexed keywords

I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; POLYUBIQUITIN; UBIQUITIN; WITHAFERIN A; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEMO PROTEIN, MOUSE; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR; WITHANOLIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CELLS BY BODY ANATOMY; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IONIZING RADIATION; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; EMBRYONIC STEM CELL; ENZYME IMMUNOASSAY; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GEL MOBILITY SHIFT ASSAY; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; PRE B LYMPHOCYTE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EMBRYONIC STEM CELLS; FIBROBLASTS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; I-KAPPA B KINASE; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; NF-KAPPA B; PRECURSOR CELLS, B-LYMPHOID; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN; UBIQUITINATION; WITHANOLIDES;

EID: 84921282213     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.09.034     Document Type: Article

References (77)

1. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. 10.1038/nature04870.
2. Karin M., Cao Y., Greten F.R., Li Z.-W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2:301-310. 10.1038/nrc780.
3. Pacifico F., Leonardi A. NF-kappaB in solid tumors. Biochem. Pharmacol. 2006, 72:1142-1152. 10.1016/j.bcp.2006.07.032.
4. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:49-62. 10.1038/nrm2083.
5. Perkins N.D. The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer 2012, 12:121-132. 10.1038/nrc3204.
6. Baeuerle P.A., Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988, 242:540-546.
7. Adhikari A., Xu M., Chen Z.J. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 2007, 26:3214-3226. 10.1038/sj.onc.1210413.
8. Kanayama A., Seth R.B., Sun L., Ea C.-K., Hong M., Shaito A., et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 2004, 15:535-548. 10.1016/j.molcel.2004.08.008.
9. Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 1995, 267:1485-1488.
10. Rothwarf D.M., Zandi E., Natoli G., Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998, 395:297-300. 10.1038/26261.
11. Spencer E., Jiang J., Chen Z.J. Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev. 1999, 13:284-294.
12. Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F., et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 1998, 93:1231-1240.
13. Senftleben U., Cao Y., Xiao G., Greten F.R., Krähn G., Bonizzi G., et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293:1495-1499. 10.1126/science.1062677.
14. Xiao G., Harhaj E.W., Sun S.C. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol. Cell 2001, 7:401-409.
15. Frankenberger M., Pforte A., Sternsdorf T., Passlick B., Baeuerle P.A., Ziegler-Heitbrock H.W. Constitutive nuclear NF-kappa B in cells of the monocyte lineage. Biochem. J. 1994, 304(Pt 1):87-94.
16. Miyamoto S., Chiao P.J., Verma I.M. Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines. Mol. Cell. Biol. 1994, 14:3276-3282.
17. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet R.J., Sledge G.W. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 1997, 17:3629-3639.
18. Bharti A.C., Shishodia S., Reuben J.M., Weber D., Alexanian R., Raj-Vadhan S., et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004, 103:3175-3184. 10.1182/blood-2003-06-2151.
19. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001, 194:1861-1874.
20. Grosjean-Raillard J., Tailler M., Adès L., Perfettini J.-L., Fabre C., Braun T., et al. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2009, 28:1099-1109. 10.1038/onc.2008.457.
21. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.-H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119. 10.1038/nature09671.
22. Shembade N., Ma A., Harhaj E.W. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010, 327:1135-1139. 10.1126/science.1182364.
23. Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003, 424:793-796. 10.1038/nature01803.
24. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511. 10.1038/35000501.
25. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R.D., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 2003, 198:851-862. 10.1084/jem.20031074.
26. Gilmore T.D., Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene 2006, 25:6887-6899. 10.1038/sj.onc.1209982.
27. Ivanenkov Y.A., Balakin K.V., Lavrovsky Y. Small molecule inhibitors of NF-κB and JAK/STAT signal transduction pathways as promising anti-inflammatory therapeutics. Mini-Rev. Med. Chem. 2011, 11:55-78. 10.2174/138955711793564079.
28. Dai S., Hirayama T., Abbas S., Abu-Amer Y. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 2004, 279:37219-37222. 10.1074/jbc.C400258200.
29. Gaurnier-Hausser A., Patel R., Baldwin A.S., May M.J., Mason N.J. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Clin. Cancer Res. 2011, 17:4661-4671. 10.1158/1078-0432.CCR-10-3310.
30. May M.J., D'Acquisto F., Madge L.A., Glöckner J., Pober J.S., Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000, 289:1550-1554.
31. Strickland I., Ghosh S. Use of cell permeable NBD peptides for suppression of inflammation. Ann. Rheum. Dis. 2006, 65(Suppl 3):iii75-iii82. 10.1136/ard.2006.058438.
32. Grover A., Shandilya A., Punetha A., Bisaria V.S., Sundar D. Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera's key metabolite withaferin A. BMC Genomics 2010, 11(Suppl 4):S25. 10.1186/1471-2164-11-S4-S25.
33. Chowdhury K., Neogy R.K. Mode of action of Withaferin A and Withanolide D. Biochem. Pharmacol. 1975, 24:919-920.
34. Shohat B., Gitter S., Abraham A., Lavie D. Antitumor activity of withaferin A (NSC-101088). Cancer Chemother. Rep. 1967, 51:271-276.
35. Ichikawa H., Takada Y., Shishodia S., Jayaprakasam B., Nair M.G., Aggarwal B.B. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol. Cancer Ther. 2006, 5:1434-1445. 10.1158/1535-7163.MCT-06-0096.
36. Oh J.H., Kwon T.K. Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int. Immunopharmacol. 2009, 9:614-619. 10.1016/j.intimp.2009.02.002.
37. Thaiparambil J.T., Bender L., Ganesh T., Kline E., Patel P., Liu Y., et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int. J. Cancer 2011, 129:2744-2755. 10.1002/ijc.25938.
38. Kaileh M., Vanden Berghe W., Heyerick A., Horion J., Piette J., Libert C., et al. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J. Biol. Chem. 2007, 282:4253-4264. 10.1074/jbc.M606728200.
39. Jackson S.S., Coughlin E.E., Coon J.J., Miyamoto S. Identifying post-translational modifications of NEMO by tandem mass spectrometry after high affinity purification. Protein Expr. Purif. 2013, 92:48-53. 10.1016/j.pep.2013.08.020.
40. Huang T.T., Feinberg S.L., Suryanarayanan S., Miyamoto S. The zinc finger domain of NEMO is selectively required for NF-kappa B activation by UV radiation and topoisomerase inhibitors. Mol. Cell. Biol. 2002, 22:5813-5825.
41. Miyamoto S., Seufzer B.J., Shumway S.D. Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells. Mol. Cell. Biol. 1998, 18:19-29.
42. Miyamoto S., Schmitt M.J., Verma I.M. Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation. Proc. Natl. Acad. Sci. USA 1994, 91:5056-5060.
43. Huang T.T., Kudo N., Yoshida M., Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc. Natl. Acad. Sci. USA 2000, 97:1014-1019.
44. Wu Z.-H., Wong E.T., Shi Y., Niu J., Chen Z., Miyamoto S., et al. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol. Cell 2010, 40:75-86. 10.1016/j.molcel.2010.09.010.
45. Hollander M., Wolfe D.A., Chicken E. Nonparametric Statistical Methods 2013, John Wiley & Sons, Hoboken, NJ.
46. Chen Z.J., Bhoj V., Seth R.B. Ubiquitin, TAK1 and IKK: is there a connection?. Cell Death Differ. 2006, 13:687-692. 10.1038/sj.cdd.4401869.
47. Takaesu G., Surabhi R.M., Park K.-J., Ninomiya-Tsuji J., Matsumoto K., Gaynor R.B. TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J. Mol. Biol. 2003, 326:105-115.
48. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412:346-351. 10.1038/35085597.
49. Ea C.-K., Deng L., Xia Z.-P., Pineda G., Chen Z.J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 2006, 22:245-257. 10.1016/j.molcel.2006.03.026.
50. Fujita H., Rahighi S., Akita M., Kato R., Sasaki Y., Wakatsuki S., et al. Mechanism underlying IκB kinase activation mediated by the linear ubiquitin chain assembly complex. Mol. Cell. Biol. 2014, 34:1322-1335. 10.1128/MCB.01538-13.
51. Laplantine E., Fontan E., Chiaravalli J., Lopez T., Lakisic G., Véron M., et al. NEMO specifically recognizes K63-linked poly-ubiquitin chains through a new bipartite ubiquitin-binding domain. EMBO J. 2009, 28:2885-2895. 10.1038/emboj.2009.241.
52. Rahighi S., Ikeda F., Kawasaki M., Akutsu M., Suzuki N., Kato R., et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell 2009, 136:1098-1109. 10.1016/j.cell.2009.03.007.
53. Wu C.-J., Conze D.B., Li T., Srinivasula S.M., Ashwell J.D. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat. Cell Biol. 2006, 8:398-406. 10.1038/ncb1384.
54. Cordier F., Grubisha O., Traincard F., Véron M., Delepierre M., Agou F. The zinc finger of NEMO is a functional ubiquitin-binding domain. J. Biol. Chem. 2009, 284:2902-2907. 10.1074/jbc.M806655200.
55. Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E., Haas T.L., et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011, 471:591-596. 10.1038/nature09816.
56. Devin A., Cook A., Lin Y., Rodriguez Y., Kelliher M., Liu Z. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 2000, 12:419-429.
57. Li H., Kobayashi M., Blonska M., You Y., Lin X. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J. Biol. Chem. 2006, 281:13636-13643. 10.1074/jbc.M600620200.
58. Mercurio F., Murray B.W., Shevchenko A., Bennett B.L., Young D.B., Li J.W., et al. IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol. Cell. Biol. 1999, 19:1526-1538.
59. Rudolph D., Yeh W.C., Wakeham A., Rudolph B., Nallainathan D., Potter J., et al. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev. 2000, 14:854-862.
60. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8:33-40. 10.1038/nrd2781.
61. Chopra A., Lavin P., Patwardhan B., Chitre D. A 32-week randomized, placebo-controlled clinical evaluation of RA-11, an Ayurvedic drug, on osteoarthritis of the knees. J. Clin. Rheumatol. 2004, 10:236-245. 10.1097/01.rhu.0000138087.47382.6d.
62. Cooley K., Szczurko O., Perri D., Mills E.J., Bernhardt B., Zhou Q., et al. Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974. PLoS One 2009, 4:e6628. 10.1371/journal.pone.0006628.
63. Werneke U. Withania somnifera: From Ayurveda towards Western medical practice: a systematic review. Recent Progress in Medicinal Plants: Search for Natural Drugs 2009, (accessed 13.6.14), Studium Press L.L.C., Houston, TX, 237-256.
64. Tarantino N., Tinevez J.-Y., Crowell E.F., Boisson B., Henriques R., Mhlanga M., et al. TNF and IL-1 exhibit distinct ubiquitin requirements for inducing NEMO-IKK supramolecular structures. J. Cell Biol. 2014, 204:231-245. 10.1083/jcb.201307172.
65. Prajapati S., Tu Z., Yamamoto Y., Gaynor R.B. IKKalpha regulates the mitotic phase of the cell cycle by modulating Aurora A phosphorylation. Cell Cycle 2006, 5:2371-2380.
66. Journo C., Bonnet A., Favre-Bonvin A., Turpin J., Vinera J., CÔté E., et al. Human T cell leukemia virus type 2 tax-mediated NF-κB activation involves a mechanism independent of Tax conjugation to ubiquitin and SUMO. J. Virol. 2013, 87:1123-1136. 10.1128/JVI.01792-12.
67. Kfoury Y., Setterblad N., El-Sabban M., Zamborlini A., Dassouki Z., El Hajj H., et al. Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome. Blood 2011, 117:190-199. 10.1182/blood-2010-05-285742.
68. Khan S., Rammeloo A.W., Heikkila J.J. Withaferin A induces proteasome inhibition, endoplasmic reticulum stress, the heat shock response and acquisition of thermotolerance. PLoS One 2012, 7:e50547. 10.1371/journal.pone.0050547.
69. Khedgikar V., Kushwaha P., Gautam J., Verma A., Changkija B., Kumar A., et al. Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone. Cell Death Dis. 2013, 4:e778. 10.1038/cddis.2013.294.
70. Yang H., Wang Y., Cheryan V.T., Wu W., Cui C.Q., Polin L.A., et al. Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo. PLoS One 2012, 7:e41214. 10.1371/journal.pone.0041214.
71. Yang H., Shi G., Dou Q.P. The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from Indian winter cherry. Mol. Pharmacol. 2007, 71:426-437. 10.1124/mol.106.030015.
72. Bargagna-Mohan P., Hamza A., Kim Y., Khuan Abby Ho Y., Mor-Vaknin N., Wendschlag N., et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem. Biol. 2007, 14:623-634. 10.1016/j.chembiol.2007.04.010.
73. Lee J., Hahm E.-R., Marcus A.I., Singh S.V. Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. Mol. Carcinog. 2013, 10.1002/mc.22110.
74. Lee J., Hahm E.-R., Singh S.V. Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinogenesis 2010, 31:1991-1998. 10.1093/carcin/bgq175.
75. Mohan R., Hammers H.J., Bargagna-Mohan P., Zhan X.H., Herbstritt C.J., Ruiz A., et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004, 7:115-122. 10.1007/s10456-004-1026-3.
76. Saha S., Islam M.K., Shilpi J.A., Hasan S. Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera's key metabolite Withaferin A. Silico Pharmacol. 2013, 1:1-9. 10.1186/2193-9616-1-11.
77. Stan S.D., Hahm E.-R., Warin R., Singh S.V. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res. 2008, 68:7661-7669. 10.1158/0008-5472.CAN-08-1510.